• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

November 10, 2022

Study: Adherence to Recommended Lung Cancer Follow-Up Screening Remains Low

Author(s):

Ashley Gallagher, Editor

Improvement is seen with a higher suspicion of disease and extended timelines, analysis demonstrates.

Adherence to follow-up to American College of Radiology recommendations for Lung CT Screening Reporting and Data System (Lung-RADS) 3 and 4A nodules and 4 weeks for Lung-RADS 4B or 4X nodules was low, but it improved with a higher suspicion of lung cancer and extended follow-up timelines, according to the results of a study published in JAMA Network Open.

Investigators also found that the association of extending the follow-up time of screen-detected nodules with outcomes for individuals who are Black, male, or smokers remains unknown.

The study included individuals who had lung cancer screening examinations between January 1, 2015, and July 31, 2020, with a follow-up through July 31, 2021, from 5 academic and community lung cancer screening sites in North Carolina. Investigators collected data from the North Carolina Lung Screening Registry, which is a National Cancer Institute-funded registry that prospectively collects data on individuals who undergo lung cancer screening at participating locations in the state.

The registry has data on individual risk factor and sociodemographic information, screening exam and follow-up information, and outcome data from data exports, electronic health records, radiology reports, and state cancer registry data.

There were 685 adults with a positive screening exam, Lung-RADS, in categories 3, 4A, 4B, and 4X.

Study participants were required to have at least 1 year of follow-up after their low-dose computed tomography examination.

Investigators performed the statistical analysis between December 2020 and March 2022.

Among the 685 individuals, 60.7% were aged at least 65 years or older, 18% were Black, 51.5% were male, and 82% were white.

Overall adherence to the recommend follow-up was 42.5% but varied by Lung-RADS category. The follow-up was 30% for Lung-RADS 3, 49.5% for Lung-RADS 4A, 68% for Lung-RADS 4B or 4X. When the follow-up time was extended, the adherence increased to 68.6% within 9 months, 77.3% within 5 months, and 80.5% within 62 days, respectively.

For Lung-RADS 3, the recommended follow-up was less likely for those who are smokers compared with those who had quit. Additionally, in Lung-RADS 4A, individuals who were Black were less likely to adhere to the recommended follow-up compared with white individuals.

For Lung-RADS 4B or 4X, individuals who were female were more likely to adhere to the follow-up compared with individuals who were male. Furthermore, individuals who are smokers were less likely to follow up for these categories than those who quit smoking.

Some limitations of the study included it being conducted in just 1 geographic area.

Additionally, individuals may have received follow-up care outside the locations where they were screened, which would not be evident in these data, according to investigators.

The investigators also added that the impact of delays in follow-up care is not well-known, so it is unclear what the impact of increased follow-up would cause for individuals.

Reference

Rivera MP, Durham DD, Long JM, et al. Receipt of recommended follow-up care after a positive lung cancer screening examination. JAMA Netw Open. 2022;5(11):e2240403. doi:10.1001/jamanetworkopen.2022.40403

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Tired scared retiree man holding chest with anginal symptoms, pallor and diaphoresis at home. Suffering male with cardiac origin pain, prexcordial pressure, arrhythmia risk, urgent medical attention - Image credit: DimaBerlin | stock.adobe.com
Image credit: Sebastian Kaulitzki | stock.adobe.com
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Related Content
Advertisement
Molecular model of pembrolizumab | Image Credit: © Dr_Microbe - stock.adobe.com
June 12th 2025

Pembrolizumab Receives FDA Approval for Treatment of Head and Neck Squamous Cell Carcinoma

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Wooden blocks spelling biosimilars -- Image credit: lexiconimages | stock.adobe.com
June 12th 2025

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Gardasil box next to syringes | Image Credit: © Unshu - stock.adobe.com
June 12th 2025

The Path to Cervical Cancer Eradication: Overcoming Barriers to HPV Vaccination

Alexandra Gerlach, Associate Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Related Content
Advertisement
Molecular model of pembrolizumab | Image Credit: © Dr_Microbe - stock.adobe.com
June 12th 2025

Pembrolizumab Receives FDA Approval for Treatment of Head and Neck Squamous Cell Carcinoma

Alexandra Gerlach, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Wooden blocks spelling biosimilars -- Image credit: lexiconimages | stock.adobe.com
June 12th 2025

Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Gardasil box next to syringes | Image Credit: © Unshu - stock.adobe.com
June 12th 2025

The Path to Cervical Cancer Eradication: Overcoming Barriers to HPV Vaccination

Alexandra Gerlach, Associate Editor
FDA Approves Tablet Formulation of Zanubrutinib for All Indications
June 11th 2025

FDA Approves Tablet Formulation of Zanubrutinib for All Indications

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.